Swiss National Bank lessened its position in shares of CVS Health Corporation (NYSE:CVS) by 0.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,799,210 shares of the pharmacy operator’s stock after selling 27,200 shares during the period. Swiss National Bank owned about 0.37% of CVS Health Corporation worth $305,684,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Horan Capital Advisors LLC. grew its holdings in CVS Health Corporation by 3.2% during the 2nd quarter. Horan Capital Advisors LLC. now owns 32,115 shares of the pharmacy operator’s stock worth $2,584,000 after acquiring an additional 1,000 shares in the last quarter. Community Bank N.A. grew its holdings in CVS Health Corporation by 7.3% during the 2nd quarter. Community Bank N.A. now owns 19,976 shares of the pharmacy operator’s stock worth $1,608,000 after acquiring an additional 1,362 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in CVS Health Corporation by 3.2% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 176,294 shares of the pharmacy operator’s stock worth $13,840,000 after acquiring an additional 5,478 shares in the last quarter. Midwest Investment Management LLC boosted its holdings in shares of CVS Health Corporation by 6.2% in the 2nd quarter. Midwest Investment Management LLC now owns 21,382 shares of the pharmacy operator’s stock valued at $1,720,000 after buying an additional 1,245 shares in the last quarter. Finally, Fiduciary Trust Co. boosted its holdings in shares of CVS Health Corporation by 1.2% in the 1st quarter. Fiduciary Trust Co. now owns 366,007 shares of the pharmacy operator’s stock valued at $28,732,000 after buying an additional 4,265 shares in the last quarter. Institutional investors own 82.04% of the company’s stock.
CVS Health Corporation (NYSE CVS) opened at $70.99 on Monday. The company has a market cap of $71,912.30, a price-to-earnings ratio of 12.43, a price-to-earnings-growth ratio of 1.22 and a beta of 0.86. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. CVS Health Corporation has a 12-month low of $66.45 and a 12-month high of $84.72.
CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health Corporation had a net margin of 2.77% and a return on equity of 16.96%. CVS Health Corporation’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.64 EPS. sell-side analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, November 3rd. Shareholders of record on Tuesday, October 24th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Monday, October 23rd. This represents a $2.00 dividend on an annualized basis and a yield of 2.82%. CVS Health Corporation’s payout ratio is currently 41.32%.
In other CVS Health Corporation news, CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the completion of the transaction, the chief financial officer now owns 141,096 shares in the company, valued at approximately $11,238,296.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jonathan C. Roberts sold 85,743 shares of the stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $83.14, for a total transaction of $7,128,673.02. Following the completion of the transaction, the chief operating officer now owns 119,555 shares of the company’s stock, valued at approximately $9,939,802.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 716,625 shares of company stock valued at $58,318,431. 0.61% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/13/swiss-national-bank-has-305-68-million-holdings-in-cvs-health-corporation-cvs.html.
Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of CVS Health Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Citigroup Inc. lowered their target price on shares of CVS Health Corporation from $88.00 to $87.00 and set a “neutral” rating for the company in a report on Thursday, August 17th. Royal Bank Of Canada assumed coverage on shares of CVS Health Corporation in a report on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 target price for the company. Jefferies Group LLC upped their target price on shares of CVS Health Corporation from $82.00 to $86.00 and gave the company a “hold” rating in a report on Friday, September 15th. Finally, Wolfe Research cut shares of CVS Health Corporation from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $89.00 to $82.00 in a report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. CVS Health Corporation has a consensus rating of “Buy” and an average target price of $85.82.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.